FCCC LOGO Faculty Publications
Thompson JA , Schneider BJ , Brahmer J , Andrews S , Armand P , Bhatia S , Budde LE , Costa L , Davies M , Dunnington D , Ernstoff MS , Frigault M , Kaffenberger BH , Lunning M , McGettigan S , McPherson J , Mohindra NA , Naidoo J , Olszanski AJ , Oluwole O , Patel SP , Pennell N , Reddy S , Ryder M , Santomasso B , Shofer S , Sosman JA , Wang Y , Weight RM , Johnson-Chilla A , Zuccarino-Catania G , Engh A
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020
J Natl Compr Canc Netw. 2020 Mar;18(3) :230-241
Back to previous list
Abstract
The NCCN Guidelines for Management of Immunotherapy-Related Toxicities provide interdisciplinary guidance on the management of immune-related adverse events (irAEs) resulting from cancer immunotherapy. These NCCN Guidelines Insights describe symptoms that may be caused by an irAE and should trigger further investigation, and summarize the NCCN Management of Immunotherapy-Related Toxicities Panel discussions for the 2020 update to the guidelines regarding immune checkpoint inhibitor-related diarrhea/colitis and cardiovascular irAEs.
Notes
1540-1413 Thompson, John A Schneider, Bryan J Brahmer, Julie Andrews, Stephanie Armand, Philippe Bhatia, Shailender Budde, Lihua E Costa, Luciano Davies, Marianne Dunnington, David Ernstoff, Marc S Frigault, Matthew Kaffenberger, Benjamin H Lunning, Matthew McGettigan, Suzanne McPherson, Jordan Mohindra, Nisha A Naidoo, Jarushka Olszanski, Anthony J Oluwole, Olalekan Patel, Sandip P Pennell, Nathan Reddy, Sunil Ryder, Mabel Santomasso, Bianca Shofer, Scott Sosman, Jeffrey A Wang, Yinghong Weight, Ryan M Johnson-Chilla, Alyse Zuccarino-Catania, Griselda Engh, Anita Journal Article United States J Natl Compr Canc Netw. 2020 Mar;18(3):230-241. doi: 10.6004/jnccn.2020.0012.